JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bartlett, G. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bartlett, G. R.
Journal of Pharmacology And Experimental Therapeutics, Vol. 93, Issue 3, 329-337, 1948
Copyright © 1948 by American Society for Pharmacology and Experimental Therapeutics


INHIBITION OF SUCCINOXIDASE BY THE VITAMIN P-LIKE FLAVONOID 2',3,4-TRIHYDROXY CHALCONE

Grant R. Bartlett 1

1 Scripps Metabolic Clinic, La Jolla, Calif.

2',3,4-trihydroxy chalcone gives a strong inhibition of rat liver succinoxidase, an effect which is greater with increasing pH. At a pH of 7.4, 1 x 10-4 M chalcone almost completely inhibits the enzyme.

The chalcone reacts with substrate activating dehydrogenase and not with the cytochrome c-cytochrome oxidase system.

The methoxy derivative, 3-methoxy-2',4-dihydroxy chalcone, is not toxic to the succinoxidase system.

The inhibition is probably due to a combination of quinoid oxidation product of the flavone with essential SH groups of the enzyme. The reaction can be prevented but not reversed by glutathione.

Although the flavone forms complexes with various metals, including copper, it did not decrease the cupric ion inhibition of the succinoxidase.

Submitted on March 15, 1948







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1948 by the American Society for Pharmacology and Experimental Therapeutics.